Barth Syndrome Foundation urgently appeals to FDA and Stealth...

In response to FDA’s request for additional clinical trials evaluating elamipretide in individuals with Barth syndrome, BSF rallies the patient community in a global advocacy campaign.(PRWeb November 18, 2020)Read the full story at https://www.prweb.com/releases/barth_syndrome_foundation_urgently_appeals_to_fda_and_stealth_biotherapeutics_to_provide_access_to_potential_therapy/prweb17471072.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news